Monopar Therapeutics Stock Profit Margin
| MNPR Stock | USD 24.53 0.81 3.20% |
Monopar Therapeutics fundamentals help investors to digest information that contributes to Monopar Therapeutics' financial success or failures. It also enables traders to predict the movement of Monopar Stock. The fundamental analysis module provides a way to measure Monopar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Monopar Therapeutics stock.
| Last Reported | Projected for Next Year |
Monopar | Profit Margin |
Monopar Therapeutics Company Profit Margin Analysis
Monopar Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Monopar Therapeutics has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Monopar Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Monopar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Monopar Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Monopar Fundamentals
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 147.27 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Shares Owned By Insiders | 42.94 % | ||||
| Shares Owned By Institutions | 24.47 % | ||||
| Number Of Shares Shorted | 25.8 K | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 31.24 X | ||||
| EBITDA | 429.04 K | ||||
| Net Income | (8.4 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 1.76 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (1.98) X | ||||
| Target Price | 27.33 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 149.6 M | ||||
| Total Asset | 7.35 M | ||||
| Retained Earnings | (60.21 M) | ||||
| Working Capital | 5.58 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
| Net Asset | 7.35 M |
About Monopar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
| 0.84 | DTIL | Precision BioSciences | PairCorr |
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.8 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | VINC | Vincerx Pharma | PairCorr |
| 0.75 | DOMH | Dominari Holdings | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.